The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.
- Antiretroviral therapy
- Peripheral neuropathy
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience